Navigation Links
Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
Date:6/2/2008

Landmark Study Shows Increased Survival for Non-Small Cell Lung Cancer

WASHINGTON, June 2 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) hailed the release of promising data from the pivotal Phase III First Line in Lung Cancer with Erbitux(R) (FLEX) Study. The data, presented at the American Society of Clinical Oncology (ASCO), showed a significant increase in overall survival in the first line treatment of patients with non-small cell lung cancer (NSCLC).

"This is very exciting news," said Laurie Fenton Ambrose, LCA President & CEO. "The FLEX data shows significant improvements in overall survival for a broad base of patients with no new safety concerns. This is so important to the lung cancer community because it will provide patients and doctors with another treatment option to consider when managing their diagnosis."

The FLEX study, conducted by Merck KGaA, enrolled more than 1,100 patients with Stage IIIb or IV NSCLC who had not previously received chemotherapy. The study included patients of all ages, regardless of their performance status (general well-being) who were diagnosed with all types of NSCLC. Erbitux(R) is a monoclonal antibody designed to inhibit the function of the epidermal growth factor receptor (EGFR). The major side effect from the drug is a rash.

Lung cancer is the leading cancer killer of both men and women in the United States with more than 162,000 deaths expected to occur in 2008, accounting for almost 30% of all cancer deaths.

"This is an important development," said David H. Johnson, MD, Deputy Director, Vanderbilt Ingram Cancer Center. "All lung cancer is notoriously difficult to treat. These results will further our understanding of NSCLC and provide a new standard of care for the lung cancer community."

For more information on the data please visit http://www.asco.org .

Lung Cancer Alliance (

SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
(Date:5/23/2013)... , May 24, 2013 3SBio Inc. ... "Company"), a leading China -based ... marketing biopharmaceutical products, announced today that, at an ... Company,s shareholders voted in favor of the proposal ... and plan of merger dated February 8, 2013, ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
(Date:5/24/2013)... May 24, 2013 Today, Zane ... Indiana Health Insurance Exchange . Zane Benefits, ... employer sponsored health benefits, is the leader in ... reimbursement arrangements . , According to Zane Benefits’ ... Affordable Care Act (ACA), health insurance coverage for ...
(Date:5/24/2013)... HealthDay Reporter , , FRIDAY, May 24 (HealthDay News) ... remarkable. But it was a physical challenge in her ... her sport. "I was an 11-year-old girl with ... was diagnosed by my orthopedic surgeon," said Lewis, who ... Society and the American Academy of Orthopaedic Surgeons so ...
(Date:5/24/2013)... 2013 KC and Monica Craichy, Founders of ... FreeRide836. Their oldest sons, Kyle and Austin Craichy, will be ... and several professional kiteboarders. , KC Craichy said he is ... miraculously come together such that virtually everyone who planned to ... 20 kite boarders will meet at Matheson Hammock Park and ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
(Date:5/24/2013)... Started in 1982, AMTC’s SHINE event is a biannual ... anniversary. SHINE is a ministry run by three generations of ... daughter, Carey Lewis Arban. , This summer’s SHINE will be ... including the New York Film Academy, The New York Conservatory ... Hollywood and Christian casting directors. They seek top talent ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Indiana Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Indiana Health Insurance Exchange 3Health News:Zane Benefits Publishes New Information on the Indiana Health Insurance Exchange 4Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2
... mathematician and his colleagues are finding ways to tell the ... cells, based on the way the cells look and move. ... and motion of single cells for laboratory analysis. ... an entirely new way of identifying cell abnormalities, including cancer. ...
... TUESDAY, Jan. 25 (HealthDay News) -- Elderly patients with ... emergency department often do not comprehend why they are ... or nurses, a new study finds. U.S. researchers ... an emergency department and found that those with cognitive ...
... School of Medicine leaders joined state, community and university ... grant to improve children,s health. The grant project will ... enhancing physical, emotional, social, cognitive and behavioral development services. ... in Children,s Health) will serve children ages birth to ...
... -- Epilepsy was the likely cause of hallucinations experienced by ... study. Researchers reached the conclusion that Chopin had temporal ... hallucinations -- including his description of a "cohort of phantoms" ... pupils and friends such as George Sand. In one ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... of external defibrillators, the U.S. Food and Drug Administration is ... devices should be held to stricter standards. Over the ... devices, which are used to shock a patient in cardiac ...
... a blood test to measure the level of a substance ... following acute coronary syndromes. This is the conclusion of a ... coronary syndromes, such as myocardial infarction and unstable angina, are ... death in Sweden for both women and men. "The ...
Cached Medicine News:Health News:Researchers use cell 'profiling' to detect abnormalities -- including cancer 2Health News:Researchers use cell 'profiling' to detect abnormalities -- including cancer 3Health News:Elderly With Dementia, Delirium Confused by ER Visits: Study 2Health News:Federal grant helps LAUNCH improvements in children's health 2Health News:FDA Looking for Tougher Standards for External Defibrillators 2Health News:Ultrasound and a blood test can increase survival after myocardial infarction 2
Anti-RSV IgA Assay (ELISA)....
... SAS RSV antigen test is ... for the presumptive qualitative detection ... from nasopharyngeal specimens in neonatal ... 15 minute test has a ...
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Medicine Products: